Abstract
Biopsy tissue analysis is central for therapeutic decision-making in the era of precision oncology. Insufficient tumor tissue and incomplete genotyping, which prevents access to targeted therapies, are considerable challenges in lung cancer patients. Liquid biopsies, a non-invasive alternative to tissue, offer more accurate capture of tumor heterogeneity and greater flexibility for real-time disease monitoring at significantly reduced cost and risk to patients. Early evidence suggests that liquid biopsies can detect actionable biomarkers in non-small cell lung cancer (NSCLC).
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call